UroGen Pharma Ltd. CEO Ron Bentsur's 2018 pay jumps 202% to $6M
UroGen Pharma Ltd. reports 2018 executive compensation
By ExecPay News
Published: April 26, 2019
UroGen Pharma Ltd. reported fiscal year 2018 executive compensation information on April 26, 2019.
In 2018, seven executives at UroGen Pharma Ltd. received on average a compensation package of $3.3M, a 140% increase compared to previous year.
Average pay of disclosed executives at UroGen Pharma Ltd.
Ron Bentsur, Chief Executive Officer, received $6M in total, which increased by 202% compared to 2017.
Stephen Mullennix, Chief Financial Officer, received a compensation package of $4.3M. 59% of the compensation package, or $2.6M, was in option awards.
Gil Hakim, Former President, earned $3.9M in 2018, a 187% increase compared to previous year.
Gary Titus, Chief Financial Officer, received $3.5M in 2018, which increases by 224% compared to 2017.
Peter P. Pfreundschuh, Chief Financial Officer, earned $2.5M in 2018.
Peter Pfreundschuh, Chief Financial Officer, received $2.5M in 2018.
Mark Schoenberg, Chief Medical Officer, earned $300K in 2018, a 72% decrease compared to previous year.
Related executives
Gil Hakim
UroGen Pharma Ltd.
Former President
Stephen Mullennix
UroGen Pharma Ltd.
Chief Operating Officer
Mark Schoenberg
UroGen Pharma Ltd.
Chief Medical Officer
Gary Titus
UroGen Pharma Ltd.
Chief Financial Officer
Peter Pfreundschuh
UroGen Pharma Ltd.
Chief Financial Officer
Ron Bentsur
UroGen Pharma Ltd.
Chief Executive Officer
Peter Pfreundschuh
UroGen Pharma Ltd.
Chief Financial Officer
You may also like
Source: SEC filing on April 26, 2019.